Skip to main content
SpringerLink
Log in

Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been shown to improve the outcome in all age groups with newly diagnosed diffuse large B-cell lymphoma (DLBCL). We conducted a retrospective analysis to evaluate the impact of this combination therapy on DLBCL outcomes in Korea. From October 2001 to June 2004, newly diagnosed DLBCL patients in nine Korean institutes were included. All of these 81 patients were treated with three or more cycles of rituximab plus CHOP (R-CHOP) combination chemotherapy (R group), and followed for a minimum of 12 months. For comparison, a historical cohort of patients was used and analyzed for “Clinicopathologic characteristics of Korean non-Hodgkin’s lymphomas (NHLs) based on Revised American Lymphoma (REAL) classification” in 1999. Among the 1,098 NHL patients, the data of 214 DLBCL patients, who were treated with CHOP chemotherapy in first-line, were analyzed (C group). We compared outcomes between the C group and the R group. A total of 295 patients were evaluated (C group, 214; R group, 81). The complete response (CR) rate was higher in R group (73 vs 91%, p=0.001). The 2-year event-free survival (EFS) rate was significantly higher in R group (78 vs 85%, p=0.0194). This survival benefit was maintained in high-risk patients according to the international prognostic index (IPI) (p=0.0039), regardless of age. However, there was no significant difference in low-risk patients. The addition of rituximab to CHOP combination chemotherapy for DLBCLs showed improved outcomes, particularly in high-risk group according to the IPI. Long-term follow-up results will be needed to confirm these results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Chang KL, Arber DA, Weiss LM (1996) CD20: a review. Appl Immunohistochem 4:1–15

    CAS  Google Scholar 

  2. Cheson BD (2005) What is new in lymphoma? Cancer J Clin 54:260–272

    Article  Google Scholar 

  3. Coiffier B (2005) Current strategies for the treatment of diffuse large B cell lymphoma. Curr Opin Hematol 12:259–265

    Article  PubMed  CAS  Google Scholar 

  4. Demidem A, Hanna N, Hariharan H et al (1995) Chimeric anti-CD20 antibody (IDEC C2B8) is apoptotic and sensitizes drug-resistant human B cell lymphomas to the cytotoxic effect of CDDP, VP-16 and toxins. FASEB J 9:A206

    Google Scholar 

  5. Feugier P, Van Hoof A, Sebban C et al (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. J Clin Oncol 23:4117–4126

    Article  PubMed  CAS  Google Scholar 

  6. Fisher RI, Gaynor ER, Dahlberg S et al (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherpay regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328:1002–1006

    Article  PubMed  CAS  Google Scholar 

  7. Fisher RI, Miller TP, and O’Connor OA (2004) Diffuse aggressive lymphoma. Hematology 221–236

  8. Foran JM, Rochatiner AZS, Conningham et al (2000) European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317–324

    PubMed  CAS  Google Scholar 

  9. Gordon LI, Harrington D, Andersen J et al (1992) Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin’s lymphoma. N Engl J Med 327:1342–1349

    Article  PubMed  CAS  Google Scholar 

  10. Hennessy BT, Hanrahan EO, Daly PA (2004) Non-Hodgkin’s lymphoma: an update. Lancet Oncol 5:341–353

    Article  PubMed  Google Scholar 

  11. Jaffe ES, Harris NL, Stein H et al (2001) Tumours of haematopoietic and lymphoid tissue in World Health Organization Classification of Tumors. IARC Press, Lyon, pp 171–174

    Google Scholar 

  12. Kang YK, Kim BS, Kim TW et al (1999) Clinicopathologic characteristics of Korean non-Hodgkin’s lymphomas based on REAL classification. J Korean Cancer Assoc 31:641–652

    Google Scholar 

  13. Ko YH, Kim CW, Park CS et al (1998) REAL classification of malignant lymphoma in the Republic of Korea. Cancer 83:806–812

    Article  PubMed  CAS  Google Scholar 

  14. Lee SS, Cho KJ, Kim CW, Kang YK (1999) Clinicopathological analysis of 501 non-Hodgkin’s lymphomas in Korea according to the revised European–American classification of lymphoid neoplasms. Histopathology 35:345–354

    Article  PubMed  CAS  Google Scholar 

  15. McLaughlin P, Grillo-Lopez AJ, Link BK et al (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825–2833

    PubMed  CAS  Google Scholar 

  16. Mounier N, Briere J, Gisselbrecht C et al (2003) Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101:4279–4284

    Article  PubMed  CAS  Google Scholar 

  17. Pfreundschuh MG, Trumper L, Ma D et al (2004) Randomized intergroup trial of first line treatment for patients <60 years with diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab — early stopping after the first interim analysis. J Clin Oncol 22:14S (abstract no. 6500)

    Google Scholar 

  18. Reff ME, Carner K, Chambers KS, Chinn PC et al (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435–445

    PubMed  CAS  Google Scholar 

  19. Sehn LH, Donaldson J, Chhanabhai M et al (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23:5027–5033

    Article  PubMed  CAS  Google Scholar 

  20. Shan D, Ledbetter JA, Press OW (1998) Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91:1644–1652

    PubMed  CAS  Google Scholar 

  21. Tobinai K, Igarashi T, Itoh K et al (2004) Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol 15:821–830

    Article  PubMed  CAS  Google Scholar 

  22. Vose JM, Link BK, Grossbard ML et al (2001) Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J Clin Oncol 19:389–397

    PubMed  CAS  Google Scholar 

  23. Wohrer S, Puspok A, Drach J et al (2004) Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma. Ann Oncol 15:1086–1090

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Korea Cancer Center Hospital, Seoul, South Korea

    Y. H. Park, B. Y. RYoo & S. H. Yang

  2. Chonnam National University, Kwangju, South Korea

    J. J. Lee, Y. K. Kim & H. J. Kim

  3. Department of Internal Medicine, Division of Medical Oncology, Asan Medical Center, University of Ulsan College of Medicine, 388-1, Poongnap-Dong, Songpa-Gu, Seoul, 138-736, South Korea

    M. H. Ryu, C. W. Suh & Y. K. Kang

  4. Seoul National University, Seoul, South Korea

    S. Y. Kim, D. S. Heo & Y. J. Bang

  5. Kyungpook National University, Taegu, South Korea

    D. H. Kim, J. K. Kim & S. K. Sohn

  6. Kyemyung University, Taegu, South Korea

    Y. R. Do & H. S. Song

  7. Yeungnam University, Kyongsan, Kyongbuk, South Korea

    K. H. Lee

  8. Sungkyun-kwan University, Seoul, South Korea

    S. J. Oh

  9. Gyeongsang National University, Chinju, South Korea

    W. S. Lee

Authors
  1. Y. H. Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. J. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. H. Ryu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Y. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. H. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y. R. Do
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K. H. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. J. Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Y. K. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C. W. Suh
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. D. S. Heo
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. B. Y. RYoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J. K. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. H. S. Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. W. S. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. H. J. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Y. J. Bang
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. S. H. Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. S. K. Sohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Y. K. Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Lymphoma Study Division of the Korean Cancer Study Group

Corresponding author

Correspondence to Y. K. Kang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lymphoma Study Division of the Korean Cancer Study Group., Park, Y.H., Lee, J.J. et al. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients. Ann Hematol 85, 257–262 (2006). https://doi.org/10.1007/s00277-005-0060-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-005-0060-6

Keywords

Search

Navigation